Open Access

Clinical significance of tumor expression of major histocompatibility complex class I-related chains A and B (MICA/B) in gastric cancer patients

  • Authors:
    • Carolina Hager Ribeiro
    • Karina Kramm
    • Felipe Gálvez-Jirón
    • Víctor Pola
    • Marco Bustamante
    • Hector R. Contreras
    • Andrea Sabag
    • Macarena Garrido-Tapia
    • Carolina J. Hernández
    • Roberto Zúñiga
    • Norberto Collazo
    • Pablo Hernán Sotelo
    • Camila Morales
    • Luis Mercado
    • Diego Catalán
    • Juan Carlos Aguillón
    • María Carmen Molina
  • View Affiliations

  • Published online on: December 23, 2015     https://doi.org/10.3892/or.2015.4510
  • Pages: 1309-1317
  • Copyright: © Ribeiro et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastric cancer (GC) is the third most common cause of cancer death worldwide. Natural killer cells play an important role in the immune defense against transformed cells. They express the activating receptor NKG2D, whose ligands belong to the MIC and ULBP/RAET family. Although it is well established that these ligands are generally expressed in tumors, the association between their expression in the tumor and gastric mucosa and clinical parameters and prognosis of GC remains to be addressed. In the present study, MICA and MICB expression was analyzed, by flow cytometry, in 23 and 20 pairs of gastric tumor and adjacent non-neoplasic gastric mucosa, respectively. Additionally, ligands expression in 13 tumors and 7 gastric mucosa samples from GC patients were evaluated by immunohistochemistry. The mRNA levels of MICA in 9 pairs of tumor and mucosa were determined by quantitative PCR. Data were associated with the clinicopathological characteristics and the patient outcome. MICA expression was observed in 57% of tumors (13/23) and 44% of mucosal samples (10/23), while MICB was detected in 50% of tumors (10/20) and 45% of mucosal tissues (9/20). At the protein level, ligand expression was significantly higher in the tumor than in the gastric mucosa. MICA mRNA levels were also increased in the tumor as compared to the mucosa. However, clinicopathological analysis indicated that, in patients with tumors >5 cm, the expression of MICA and MICB in the tumor did not differ from that of the mucosa, and tumors >5 cm showed significantly higher MICA and MICB expression than tumors ≤5 cm. Patients presenting tumors >5 cm that expressed MICA and MICB had substantially shorter survival than those with large tumors that did not express these ligands. Our results suggest that locally sustained expression of MICA and MICB in the tumor may contribute to the malignant progression of GC and that expression of these ligands predicts an unfavorable prognosis in GC patients presenting large tumors.

References

1 

International Agency for Research on Cancer and World Health Organization: World Cancer Report 2014. Stewart BW and Wild C: IARC Press; Lyon: 2014

2 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Arkenau HT: Gastric cancer in the era of molecularly targeted agents: Current drug development strategies. J Cancer Res Clin Oncol. 135:855–866. 2009. View Article : Google Scholar : PubMed/NCBI

4 

Ogino S, Galon J, Fuchs CS and Dranoff G: Cancer immunology–analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 8:711–719. 2011. View Article : Google Scholar : PubMed/NCBI

5 

Trinchieri G: Natural killer cells wear different hats: Effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Semin Immunol. 7:83–88. 1995. View Article : Google Scholar : PubMed/NCBI

6 

Gasser S and Raulet DH: Activation and self-tolerance of natural killer cells. Immunol Rev. 214:130–142. 2006. View Article : Google Scholar : PubMed/NCBI

7 

Anfossi N, André P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, et al: Human NK cell education by inhibitory receptors for MHC class I. Immunity. 25:331–342. 2006. View Article : Google Scholar : PubMed/NCBI

8 

Raulet DH and Guerra N: Oncogenic stress sensed by the immune system: Role of natural killer cell receptors. Nat Rev Immunol. 9:568–580. 2009. View Article : Google Scholar : PubMed/NCBI

9 

Nausch N and Cerwenka A: NKG2D ligands in tumor immunity. Oncogene. 27:5944–5958. 2008. View Article : Google Scholar : PubMed/NCBI

10 

Burgess SJ, Maasho K, Masilamani M, Narayanan S, Borrego F and Coligan JE: The NKG2D receptor: Immunobiology and clinical implications. Immunol Res. 40:18–34. 2008. View Article : Google Scholar : PubMed/NCBI

11 

Champsaur M and Lanier LL: Effect of NKG2D ligand expression on host immune responses. Immunol Rev. 235:267–285. 2010. View Article : Google Scholar : PubMed/NCBI

12 

Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S and Raulet DH: A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood. 105:4416–4423. 2005. View Article : Google Scholar : PubMed/NCBI

13 

Ogasawara K and Lanier LL: NKG2D in NK and T cell-mediated immunity. J Clin Immunol. 25:534–540. 2005. View Article : Google Scholar : PubMed/NCBI

14 

Diefenbach A, Jamieson AM, Liu SD, Shastri N and Raulet DH: Ligands for the murine NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 1:119–126. 2000. View Article : Google Scholar

15 

Duan X, Deng L, Chen X, Lu Y, Zhang Q, Zhang K, Hu Y, Zeng J and Sun W: Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol. 28:466–474. 2011. View Article : Google Scholar

16 

Kohga K, Takehara T, Tatsumi T, Miyagi T, Ishida H, Ohkawa K, Kanto T, Hiramatsu N and Hayashi N: Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res. 69:8050–8057. 2009. View Article : Google Scholar : PubMed/NCBI

17 

Tamaki S, Sanefuzi N, Kawakami M, Aoki K, Imai Y, Yamanaka Y, Yamamoto K, Ishitani A, Hatake K and Kirita T: Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients. Hum Immunol. 69:88–93. 2008. View Article : Google Scholar : PubMed/NCBI

18 

Fuertes MB, Girart MV, Molinero LL, Domaica CI, Rossi LE, Barrio MM, Mordoh J, Rabinovich GA and Zwirner NW: Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol. 180:4606–4614. 2008. View Article : Google Scholar : PubMed/NCBI

19 

Groh V, Wu J, Yee C and Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 419:734–738. 2002. View Article : Google Scholar : PubMed/NCBI

20 

Salih HR, Rammensee HG and Steinle A: Cutting edge: Down-regulation of MICA on human tumors by proteolytic shedding. J Immunol. 169:4098–4102. 2002. View Article : Google Scholar : PubMed/NCBI

21 

Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, Girardi M and Hayday AC: Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol. 6:928–937. 2005. View Article : Google Scholar : PubMed/NCBI

22 

Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K and Plymate SR: Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest. 114:560–568. 2004. View Article : Google Scholar : PubMed/NCBI

23 

McGilvray RW, Eagle RA, Rolland P, Jafferji I, Trowsdale J and Durrant LG: ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patients. Int J Cancer. 127:1412–1420. 2010. View Article : Google Scholar : PubMed/NCBI

24 

Osaki T, Saito H, Yoshikawa T, Matsumoto S, Tatebe S, Tsujitani S and Ikeguchi M: Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer. Clin Cancer Res. 13:382–387. 2007. View Article : Google Scholar : PubMed/NCBI

25 

Saito H, Osaki T and Ikeguchi M: Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer. Gastric Cancer. 15:27–33. 2012. View Article : Google Scholar

26 

Kuroda H, Saito H and Ikeguchi M: Decreased number and reduced NKG2D expression of Vdelta1 gammadelta T cells are involved in the impaired function of Vdelta1 gammadelta T cells in the tissue of gastric cancer. Gastric Cancer. 15:433–439. 2012. View Article : Google Scholar : PubMed/NCBI

27 

Zhao S, Wang H, Nie Y, Mi Q, Chen X and Hou Y: Midkine upregulates MICA/B expression in human gastric cancer cells and decreases natural killer cell cytotoxicity. Cancer Immunol Immunother. 61:1745–1753. 2012. View Article : Google Scholar : PubMed/NCBI

28 

Park SW, Bae JH, Kim SD, Son YO, Kim JY, Park HJ, Lee CH, Park DY, Kim JY, Lee MK, et al: Comparison of level of NKG2D ligands between normal and tumor tissue using multiplex RT-PCR. Cancer Invest. 25:299–307. 2007. View Article : Google Scholar : PubMed/NCBI

29 

Mimura K, Kamiya T, Shiraishi K, Kua LF, Shabbir A, So J, Yong WP, Suzuki Y, Yoshimoto Y, Nakano T, et al: Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer. Int J Cancer. 135:1390–1398. 2014. View Article : Google Scholar : PubMed/NCBI

30 

Groh V, Bahram S, Bauer S, Herman A, Beauchamp M and Spies T: Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA. 93:12445–12450. 1996. View Article : Google Scholar : PubMed/NCBI

31 

Washington K: 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 17:3077–3079. 2010. View Article : Google Scholar : PubMed/NCBI

32 

Bethke J, Rojas V, Berendsen J, Cárdenas C, Guzmán F, Gallardo JA and Mercado L: Development of a new antibody for detecting natural killer enhancing factor (NKEF)-like protein in infected salmonids. J Fish Dis. 35:379–388. 2012. View Article : Google Scholar : PubMed/NCBI

33 

Santana PA, Álvarez CA, Guzmán F and Mercado L: Development of a sandwich ELISA for quantifying hepcidin in Rainbow trout. Fish Shellfish Immunol. 35:748–755. 2013. View Article : Google Scholar : PubMed/NCBI

34 

Vogel C and Marcotte EM: Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 13:227–232. 2012.PubMed/NCBI

35 

Zu H, Wang F, Ma Y and Xue Y: Stage-stratified analysis of prognostic significance of tumor size in patients with gastric cancer. PLoS One. 8:e545022013. View Article : Google Scholar : PubMed/NCBI

36 

Waldhauer I and Steinle A: NK cells and cancer immunosurveillance. Oncogene. 27:5932–5943. 2008. View Article : Google Scholar : PubMed/NCBI

37 

Raulet DH: Missing self recognition and self tolerance of natural killer (NK) cells. Semin Immunol. 18:145–150. 2006. View Article : Google Scholar : PubMed/NCBI

38 

Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, Yamaguchi K, Baba T, Fujii S and Konishi I: Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: High expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother. 58:641–652. 2009. View Article : Google Scholar

39 

Paschen A1, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, et al: Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res. 15:5208–5215. 2009. View Article : Google Scholar : PubMed/NCBI

40 

Rebmann V, Schütt P, Brandhorst D, Opalka B, Moritz T, Nowrousian MR and Grosse-Wilde H: Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin Immunol. 123:114–120. 2007. View Article : Google Scholar : PubMed/NCBI

41 

Nakamura K, Ueyama T, Yao T, Xuan ZX, Ambe K, Adachi Y, Yakeishi Y, Matsukuma A and Enjoji M: Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer. 70:1030–1037. 1992. View Article : Google Scholar : PubMed/NCBI

42 

Siewert JR, Böttcher K, Stein HJ and Roder JD: Relevant prognostic factors in gastric cancer: Ten-year results of the German Gastric Cancer Study. Ann Surg. 228:449–461. 1998. View Article : Google Scholar : PubMed/NCBI

43 

Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N and Kitano S: Pathology and prognosis of gastric carcinoma: Well versus poorly differentiated type. Cancer. 89:1418–1424. 2000. View Article : Google Scholar : PubMed/NCBI

44 

Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA and Hamilton SM: Gastric adenocarcinoma: Review and considerations for future directions. Ann Surg. 241:27–39. 2005.

45 

McGilvray RW, Eagle RA, Watson NF, Al-Attar A, Ball G, Jafferji I, Trowsdale J and Durrant LG: NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res. 15:6993–7002. 2009. View Article : Google Scholar : PubMed/NCBI

46 

Wang C, Zhou XJ, Li YY, Wan J, Yang LY and Li GH: Effect of vasoactive intestinal peptide (VIP) on NKG2D signal pathway and its contribution to immune escape of MKN45 cells. Sci World J. 2013:4295452013.

47 

El-Gazzar A, Groh V and Spies T: Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer. J Immunol. 191:1509–1515. 2013. View Article : Google Scholar : PubMed/NCBI

48 

Lee JC, Lee KM, Kim DW and Heo DS: Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 172:7335–7340. 2004. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

March 2016
Volume 35 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ribeiro, C.H., Kramm, K., Gálvez-Jirón, F., Pola, V., Bustamante, M., Contreras, H.R. ... Molina, M.C. (2016). Clinical significance of tumor expression of major histocompatibility complex class I-related chains A and B (MICA/B) in gastric cancer patients. Oncology Reports, 35, 1309-1317. https://doi.org/10.3892/or.2015.4510
MLA
Ribeiro, C. H., Kramm, K., Gálvez-Jirón, F., Pola, V., Bustamante, M., Contreras, H. R., Sabag, A., Garrido-Tapia, M., Hernández, C. J., Zúñiga, R., Collazo, N., Sotelo, P. H., Morales, C., Mercado, L., Catalán, D., Aguillón, J. C., Molina, M. C."Clinical significance of tumor expression of major histocompatibility complex class I-related chains A and B (MICA/B) in gastric cancer patients". Oncology Reports 35.3 (2016): 1309-1317.
Chicago
Ribeiro, C. H., Kramm, K., Gálvez-Jirón, F., Pola, V., Bustamante, M., Contreras, H. R., Sabag, A., Garrido-Tapia, M., Hernández, C. J., Zúñiga, R., Collazo, N., Sotelo, P. H., Morales, C., Mercado, L., Catalán, D., Aguillón, J. C., Molina, M. C."Clinical significance of tumor expression of major histocompatibility complex class I-related chains A and B (MICA/B) in gastric cancer patients". Oncology Reports 35, no. 3 (2016): 1309-1317. https://doi.org/10.3892/or.2015.4510